Personalized mRNA vaccine for refractory rhabdomyosarcoma
Part of Cancer clinical trials.
This trial tests a personalized mRNA vaccine for people with rhabdomyosarcoma that hasn't responded to other treatments. The vaccine is designed to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rhabdomyosarcoma, a type of muscle cancer, confirmed by tests.
- You need to be 6 years old or older.
- There should be no standard treatments that work for you anymore.
- Doctors expect you to live at least 6 more months.
- You must be able to do most daily activities on your own or with little help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor's unique gene fusion. It's for people with certain sarcomas that have spread and are now in remission or stable after standard treatment. The vaccine aims to help your immune system keep the cancer from coming back.
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
This trial tests a personalized vaccine made from your own tumor tissue. The goal is to help your immune system fight cancer and to improve the response to PD-1 inhibitor therapy.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.